Effects of polypharmacy and anticholinergic/sedative drugs on the physical/cognitive/mental related outcomes of community-dwelling elderly people : The Kawasaki Wellbeing Project
AIM: To assess the burdens of polypharmacy and the drug burden index in community-dwelling elder people.
METHODS: The survey was conducted on 396 participants who participated in The Kawasaki Wellbeing Project from March to December 2017. We investigated the associations between the drug burden and the physical/cognitive/mental outcomes. The drug burden was determined by calculating the number of medications and the drug burden index (DBI) based on the use of anticholinergic and sedative drugs. A multivariate regression analysis was conducted for the outcome measures ADL, IADL, MMSE, J-CHS, and EQ5D5L after adjusting for the sex, age, number of diseases, education level, smoking history, and alcohol history.
RESULTS: A total of 389 subjects were analyzed, the mean age of the population was 86 years old, and 187 people (48%) were male. Polypharmacy was reported in 243 people (62%), and DBI exposure was reported for 142 people (36.5%). We found that this population was physically healthy, with a median ADL of 100, and had high quality of life, with a median EQ5D5L of 0.895. Polypharmacy was found to be related to the J-CHS (β: 0.04) and EQ5D5L (-0.01). The DBI was also related to the EQ5D5L (-0.04).
CONCLUSION: These results showed that even though this population was healthier than the general Japanese elderly population, the drug burden of polypharmacy and high dosages of anticholinergic/sedative drugs exerted significant negative effects on frailty and the quality of life. Additional research should be conducted to investigate the long-term effects of polypharmacy and anticholinergic/sedative drugs on elderly people.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics - 56(2019), 4 vom: 01., Seite 504-515 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Tanaka, Asahi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aged |
|---|
| Anmerkungen: |
Date Completed 17.03.2020 Date Revised 17.03.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3143/geriatrics.56.504 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM303643684 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM303643684 | ||
| 003 | DE-627 | ||
| 005 | 20231225113251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.3143/geriatrics.56.504 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1012.xml |
| 035 | |a (DE-627)NLM303643684 | ||
| 035 | |a (NLM)31761857 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Tanaka, Asahi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of polypharmacy and anticholinergic/sedative drugs on the physical/cognitive/mental related outcomes of community-dwelling elderly people |b The Kawasaki Wellbeing Project |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.03.2020 | ||
| 500 | |a Date Revised 17.03.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: To assess the burdens of polypharmacy and the drug burden index in community-dwelling elder people | ||
| 520 | |a METHODS: The survey was conducted on 396 participants who participated in The Kawasaki Wellbeing Project from March to December 2017. We investigated the associations between the drug burden and the physical/cognitive/mental outcomes. The drug burden was determined by calculating the number of medications and the drug burden index (DBI) based on the use of anticholinergic and sedative drugs. A multivariate regression analysis was conducted for the outcome measures ADL, IADL, MMSE, J-CHS, and EQ5D5L after adjusting for the sex, age, number of diseases, education level, smoking history, and alcohol history | ||
| 520 | |a RESULTS: A total of 389 subjects were analyzed, the mean age of the population was 86 years old, and 187 people (48%) were male. Polypharmacy was reported in 243 people (62%), and DBI exposure was reported for 142 people (36.5%). We found that this population was physically healthy, with a median ADL of 100, and had high quality of life, with a median EQ5D5L of 0.895. Polypharmacy was found to be related to the J-CHS (β: 0.04) and EQ5D5L (-0.01). The DBI was also related to the EQ5D5L (-0.04) | ||
| 520 | |a CONCLUSION: These results showed that even though this population was healthier than the general Japanese elderly population, the drug burden of polypharmacy and high dosages of anticholinergic/sedative drugs exerted significant negative effects on frailty and the quality of life. Additional research should be conducted to investigate the long-term effects of polypharmacy and anticholinergic/sedative drugs on elderly people | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Anticholinergic | |
| 650 | 4 | |a Drug burden | |
| 650 | 4 | |a Polypharmacy | |
| 650 | 4 | |a Sedative | |
| 650 | 7 | |a Cholinergic Antagonists |2 NLM | |
| 650 | 7 | |a Hypnotics and Sedatives |2 NLM | |
| 700 | 1 | |a Arai, Yasumichi |e verfasserin |4 aut | |
| 700 | 1 | |a Hirata, Takumi |e verfasserin |4 aut | |
| 700 | 1 | |a Abe, Yukiko |e verfasserin |4 aut | |
| 700 | 1 | |a Oguma, Yuko |e verfasserin |4 aut | |
| 700 | 1 | |a Urushihara, Hisashi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics |d 1993 |g 56(2019), 4 vom: 01., Seite 504-515 |w (DE-627)NLM000286516 |x 0300-9173 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2019 |g number:4 |g day:01 |g pages:504-515 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3143/geriatrics.56.504 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2019 |e 4 |b 01 |h 504-515 | ||